Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Amortization - Intangibles: 2014-2018

Historic Amortization - Intangibles for Viking Therapeutics (VKTX) over the last 4 years, with Jun 2018 value amounting to $146,000.

  • Viking Therapeutics' Amortization - Intangibles fell 56.68% to $146,000 in Q2 2018 from the same period last year, while for Jun 2018 it was $919,000, marking a year-over-year decrease of 43.64%. This contributed to the annual value of $404,000 for FY2018, which is 68.51% down from last year.
  • According to the latest figures from Q2 2018, Viking Therapeutics' Amortization - Intangibles is $146,000, which was down 43.41% from $258,000 recorded in Q1 2018.
  • In the past 5 years, Viking Therapeutics' Amortization - Intangibles ranged from a high of $524,977 in Q2 2016 and a low of $6,379 during Q1 2014.
  • Moreover, its 3-year median value for Amortization - Intangibles was $368,828 (2016), whereas its average is $347,509.
  • In the last 5 years, Viking Therapeutics' Amortization - Intangibles soared by 2,595.64% in 2015 and then plummeted by 56.68% in 2018.
  • Over the past 5 years, Viking Therapeutics' Amortization - Intangibles (Quarterly) stood at $294,310 in 2014, then declined by 18.28% to $240,516 in 2015, then skyrocketed by 79.29% to $431,227 in 2016, then slumped by 39.94% to $259,000 in 2017, then slumped by 56.68% to $146,000 in 2018.
  • Its last three reported values are $146,000 in Q2 2018, $258,000 for Q1 2018, and $259,000 during Q4 2017.